VERA
Vera Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$3.13B
P/E Ratio
—
EPS
$-4.66
Beta
1.17
52W High
$56.05
52W Low
$18.76
50-Day MA
$41.30
200-Day MA
$33.91
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Vera Therapeutics Inc
Vera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immune diseases in the United States. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-315.00M |
| Operating Margin | 0.00% |
| Return on Equity | -50.70% |
| Return on Assets | -28.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $8.48 |
| Price-to-Book | 5.34 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -3.60 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $71.71M |
| Float | $51.44M |
| % Insiders | 0.94% |
| % Institutions | 115.23% |
Historical Volatility
HV 10-Day
59.53%
HV 20-Day
55.13%
HV 30-Day
50.05%
HV 60-Day
48.89%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($79.00 target)
1
Strong Buy12
Buy1
HoldData last updated: 4/14/2026